Moreover, while systemic delivery of AMPK-activating treatments has been shown to reduce lesion size, the delivery of these treatments was over the entire course of the atherosclerosis progression model (18, 19), and the contribution of myeloid AMPK was not addressed. This evidence concerns the gene PRKAA1 and atherosclerosis.